ATS 2021 will feature presentations of original research from accepted abstracts. Mini Symposia and Thematic Poster Sessions are abstract based sessions.
Please use the form below to browse scientific abstracts and case reports accepted for ATS 2021. Abstracts presented at the ATS 2021 will be published in the Online Abstract Issue of the American Journal of Respiratory and Critical Care Medicine, Volume 203, May 3, 2021.
Search Tips:
- Use the keyword search to search by keyword or author's name.
- Filter your search results by selecting the checkboxes that apply.
- Click on "Clear" to clear the form and start a new search. .
Search results will display below the form.
Integrative Genomic Analysis Highlights Potential Genetic Risk Factors for Covid-19
Session Title
TP91 - TP091 EPIDEMIOLOGY AND TRANSLATIONAL ADVANCES IN SARS-COV-2
Abstract
A3765 - Integrative Genomic Analysis Highlights Potential Genetic Risk Factors for Covid-19
Author Block: A. I. Hernandez Cordero1, X. Li1, S. Milne1, C. Yang1, Y. Bossé2, P. Joubert3, W. Timens4, M. Van den Berge5, D. Nickle6, K. Hao7, D. D. Sin1; 1Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada, 2Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Quebec, QC, Canada, 3Pathology, Quebec Heart and Lung Institute, Quebec, QC, Canada, 4Department of Pathology and Medical Biology, University of Groningen, Groningen, Netherlands, 5Pulmonary diseases, UMCG, Groningen, Netherlands, 6University of Washington, Seattle, WA, United States, 7Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
RATIONALE: The genes that influence the pathophysiology of COVID-19 have yet to be identified. Association analysis has found genetic loci for COVID-191. We used integrative genomics (IG) to combine gene expression and proteomic information with COVID-19 susceptibility loci in order to identify candidate genes for this disease.
METHODS: For these analyses we used the COVID-19 Host Genetics Initiative genome-wide association (GWA) meta-analysis version 4 (COVID-19 positive versus COVID-19 negative), the Lung eQTL study2 (n=1,038), eQTLGen3 study (n=31,784) and the INTERVAL4 study (n=3,301). We conducted two IG methods (Bayesian Colocalization [coloc] and Summary Based Mendelian Randomization) to link gene and protein expression in lung and blood tissues with COVID-19 susceptibility loci. We identified the most consistently colocalized gene and conducted a Mendelian Randomization (MR) to assess the causal association of its protein (‘exposure’) with COVID-19 susceptibility (‘outcomes’). Significant MR was set as P<0.05.
RESULTS: The expression of 6 genes in lung and 12 in blood colocalized with COVID-19 susceptibility loci. SMR results demonstrated that the expression levels of 6 genes in lung tissue and 5 in blood were associated with COVID-19. Out of the candidate genes identified, two (ABO and SLC6A20) were within previously identified loci (Figure 1). Based on the SMR we found that the expression of SLC6A20 in lung was associated with a higher risk of COVID-19. Novel discovered associations included ERMP1, FCER1G, and CA11, genes which have been previously linked with respiratory diseases (i.e.: asthma) and host immune responses (i.e.: neutrophil and eosinophil counts). COVID-19 susceptibility also colocalized with plasma protein levels of ABO. Based on MR, ABO demonstrated a significant causal association (P = 2.10 × 10-5) with the risk of COVID-19 with increased levels of this protein in plasma associated with an increased risk of COVID-19. The top variant in the MR test (rs505922) was in complete linkage disequilibrium with the variant responsible for the blood O genotype, conferring reduced risk.
CONCLUSIONS: This multi-omics approach led to the discovery of novel genes associated with COVID-19. We found that the ABO protein is a causal risk factor for COVID-19, with blood group O being protective against COVID-19.
REFERENCES: 1. Ellinghaus, D. et al. N. Engl. J. Med. (2020). 2. Hao, K. et al. PLoS Genet. (2012). 3. Võsa, U. et al. bioRxiv. (2018). 4. Sun, B. B. et al. Nature. (2018)
Author Block: A. I. Hernandez Cordero1, X. Li1, S. Milne1, C. Yang1, Y. Bossé2, P. Joubert3, W. Timens4, M. Van den Berge5, D. Nickle6, K. Hao7, D. D. Sin1; 1Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada, 2Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Quebec, QC, Canada, 3Pathology, Quebec Heart and Lung Institute, Quebec, QC, Canada, 4Department of Pathology and Medical Biology, University of Groningen, Groningen, Netherlands, 5Pulmonary diseases, UMCG, Groningen, Netherlands, 6University of Washington, Seattle, WA, United States, 7Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
RATIONALE: The genes that influence the pathophysiology of COVID-19 have yet to be identified. Association analysis has found genetic loci for COVID-191. We used integrative genomics (IG) to combine gene expression and proteomic information with COVID-19 susceptibility loci in order to identify candidate genes for this disease.
METHODS: For these analyses we used the COVID-19 Host Genetics Initiative genome-wide association (GWA) meta-analysis version 4 (COVID-19 positive versus COVID-19 negative), the Lung eQTL study2 (n=1,038), eQTLGen3 study (n=31,784) and the INTERVAL4 study (n=3,301). We conducted two IG methods (Bayesian Colocalization [coloc] and Summary Based Mendelian Randomization) to link gene and protein expression in lung and blood tissues with COVID-19 susceptibility loci. We identified the most consistently colocalized gene and conducted a Mendelian Randomization (MR) to assess the causal association of its protein (‘exposure’) with COVID-19 susceptibility (‘outcomes’). Significant MR was set as P<0.05.
RESULTS: The expression of 6 genes in lung and 12 in blood colocalized with COVID-19 susceptibility loci. SMR results demonstrated that the expression levels of 6 genes in lung tissue and 5 in blood were associated with COVID-19. Out of the candidate genes identified, two (ABO and SLC6A20) were within previously identified loci (Figure 1). Based on the SMR we found that the expression of SLC6A20 in lung was associated with a higher risk of COVID-19. Novel discovered associations included ERMP1, FCER1G, and CA11, genes which have been previously linked with respiratory diseases (i.e.: asthma) and host immune responses (i.e.: neutrophil and eosinophil counts). COVID-19 susceptibility also colocalized with plasma protein levels of ABO. Based on MR, ABO demonstrated a significant causal association (P = 2.10 × 10-5) with the risk of COVID-19 with increased levels of this protein in plasma associated with an increased risk of COVID-19. The top variant in the MR test (rs505922) was in complete linkage disequilibrium with the variant responsible for the blood O genotype, conferring reduced risk.
CONCLUSIONS: This multi-omics approach led to the discovery of novel genes associated with COVID-19. We found that the ABO protein is a causal risk factor for COVID-19, with blood group O being protective against COVID-19.
REFERENCES: 1. Ellinghaus, D. et al. N. Engl. J. Med. (2020). 2. Hao, K. et al. PLoS Genet. (2012). 3. Võsa, U. et al. bioRxiv. (2018). 4. Sun, B. B. et al. Nature. (2018)
